美洲 · 区域市场 · Financial Post
Galderma’s Relfydess™ (relabotulinumtoxinA) Receives Approval in China for Frown Lines
The Chinese National Medical Products Administration (NMPA) has approved Relfydess™, the first and only ready-to-use liquid neuromodulator designed with PEARL™ Technology, for the…
在 Financial Post 阅读全文 登录后可收藏MarketNews 仅展示媒体发布的标题和摘要，全文请在出版方网站阅读。 (financialpost.com)
